|
|
Article: Better camptothecin-based strategies for malignant disease are likely to evolve.
- Article from:
- Clinical Oncology Week
- Article date:
- August 18, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 AUG 18 - (NewsRx.com & NewsRx.net) -- Better camptothecin-based strategies for malignant disease are likely to evolve.
According to a study from the United States, "Supported by detailed understanding of their mechanism of action, and facilitated by chemical manipulations that have amplified their solubility, the camptothecins have advanced to the forefront of several areas of therapeutic and developmental chemotherapy.
"Additive and synergistic laboratory interactions with other cytotoxic drugs have been exploited to allow development of camptothecin-based multidrug regimens, which are showing important activity in several malignancies," wrote ...